Concepts in glioma immunotherapy

Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid

(2016) Christian Schläger et al.   NATURE

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

Cancer immunotherapy: exploiting neoepitopes

(2015) Michael Platten et al.   CELL RESEARCH

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules

(2015) Aleksanteri Aspelund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Strategies to target drugs to gliomas and CNS metastases of solid tumors

(2015) B. Milojkovic Kerklaan et al.   JOURNAL OF NEUROLOGY

Evolving treatment options for melanoma brain metastases

(2015) Thankamma Ajithkumar et al.   LANCET ONCOLOGY

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

Prospects of immune checkpoint modulators in the treatment of glioblastoma

(2015) Matthias Preusser et al.   Nature Reviews Neurology

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

(2015) J. Schuster et al.   NEURO-ONCOLOGY

CD4+T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients

(2015) Daniel Dubinski et al.   NEURO-ONCOLOGY

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

(2015) D. A. Reardon et al.   Cancer Immunology Research

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

(2015) Serena Pellegatta et al.   Acta Neuropathologica Communications

Immunology of Relapse and Remission in Multiple Sclerosis

(2014) Lawrence Steinman   Annual Review of Immunology

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

(2014) M. Rajasagi et al.   BLOOD

Microenvironmental Clues for Glioma Immunotherapy

(2014) Michael Platten et al.   Current Neurology and Neuroscience Reports

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

mRNA-based therapeutics — developing a new class of drugs

(2014) Ugur Sahin et al.   NATURE REVIEWS DRUG DISCOVERY

Immunotherapy advances for glioblastoma

(2014) D. A. Reardon et al.   NEURO-ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages

(2013) O. Bloch et al.   CLINICAL CANCER RESEARCH

T-helper-1-cell cytokines drive cancer into senescence

(2013) Heidi Braumüller et al.   NATURE

Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial

(2013) Orin Bloch et al.   NEURO-ONCOLOGY

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

(2013) R. A. Cairns et al.   Cancer Discovery

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

(2012) Valérie Dutoit et al.   BRAIN

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Immune surveillance in the central nervous system

(2012) Shalina S Ousman et al.   NATURE NEUROSCIENCE

Developing mRNA-vaccine technologies

(2012) Thomas Schlake et al.   RNA Biology

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE